pioglitazone has been researched along with Parkinsonian Disorders in 4 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
Parkinsonian Disorders: A group of disorders which feature impaired motor control characterized by bradykinesia, MUSCLE RIGIDITY; TREMOR; and postural instability. Parkinsonian diseases are generally divided into primary parkinsonism (see PARKINSON DISEASE), secondary parkinsonism (see PARKINSON DISEASE, SECONDARY) and inherited forms. These conditions are associated with dysfunction of dopaminergic or closely related motor integration neuronal pathways in the BASAL GANGLIA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Pioglitazone-treated monkeys also showed a dose-dependent modulation of CD68-ir inflammatory cells, that was significantly decreased for 5 mg/kg treated animals compared to placebo (P = 0." | 5.37 | The PPAR-γ agonist pioglitazone modulates inflammation and induces neuroprotection in parkinsonian monkeys. ( Bondarenko, V; Brunner, K; Emborg, ME; Joers, V; Johnson, JA; Kemnitz, JW; Simmons, HA; Swanson, CR; Ziegler, TE, 2011) |
| " Pioglitazone dosing protected TH-positive neurons, closely matching the number of PPAR-gamma expressing cells in the ipsilateral SNpc." | 1.40 | Expression of peroxisome proliferator-activated receptor-gamma in the substantia nigra of hemiparkinsonian nonhuman primates. ( Emborg, M; Swanson, C, 2014) |
| "Pioglitazone-treated monkeys also showed a dose-dependent modulation of CD68-ir inflammatory cells, that was significantly decreased for 5 mg/kg treated animals compared to placebo (P = 0." | 1.37 | The PPAR-γ agonist pioglitazone modulates inflammation and induces neuroprotection in parkinsonian monkeys. ( Bondarenko, V; Brunner, K; Emborg, ME; Joers, V; Johnson, JA; Kemnitz, JW; Simmons, HA; Swanson, CR; Ziegler, TE, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Swanson, C | 1 |
| Emborg, M | 1 |
| Swanson, CR | 1 |
| Joers, V | 1 |
| Bondarenko, V | 1 |
| Brunner, K | 1 |
| Simmons, HA | 1 |
| Ziegler, TE | 1 |
| Kemnitz, JW | 1 |
| Johnson, JA | 1 |
| Emborg, ME | 1 |
| Laloux, C | 1 |
| Petrault, M | 1 |
| Lecointe, C | 1 |
| Devos, D | 1 |
| Bordet, R | 1 |
| Breidert, T | 1 |
| Callebert, J | 1 |
| Heneka, MT | 1 |
| Landreth, G | 1 |
| Launay, JM | 1 |
| Hirsch, EC | 1 |
4 other studies available for pioglitazone and Parkinsonian Disorders
| Article | Year |
|---|---|
Expression of peroxisome proliferator-activated receptor-gamma in the substantia nigra of hemiparkinsonian nonhuman primates.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Cell Count; Central Nervous System Age | 2014 |
The PPAR-γ agonist pioglitazone modulates inflammation and induces neuroprotection in parkinsonian monkeys.
Topics: Animals; Behavior, Animal; Brain; Corpus Striatum; Dopamine; Female; Hypoglycemic Agents; Inflammati | 2011 |
Differential susceptibility to the PPAR-γ agonist pioglitazone in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and 6-hydroxydopamine rodent models of Parkinson's disease.
Topics: Animals; Disease Models, Animal; Dopaminergic Neurons; Male; Mice; Mice, Inbred C57BL; Motor Activit | 2012 |
Protective action of the peroxisome proliferator-activated receptor-gamma agonist pioglitazone in a mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Administration, Oral; | 2002 |